Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;51(1):111-6.
doi: 10.3349/ymj.2010.51.1.111. Epub 2009 Dec 29.

In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains

Devrim Dundar  1 , Metin Otkun
Affiliations

In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains

Devrim Dundar et al. Yonsei Med J. 2010 Jan.

Abstract

Purpose: Combination antibiotic treatment is preferred in nosocomial infections caused by Pseudomonas aeruginosa (P. aeruginosa). In vitro synergism tests were used to choose the combinations which might be used in clinic. The aim of this study was to investigate the synergistic efficacy of synergistic antibiotic combinations in multidrug resistant P. aeruginosa strains.

Materials and methods: Synergistic efficacies of ceftazidime-tobramycin, piperacillin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-isepamycin, imipenem-ciprofloxacin and ciprofloxacin-tobramycin combinations were investigated by checkerboard technique in 12 multiple-resistant and 13 susceptible P. aeruginosa strains.

Results: The ratios of synergy were observed in ceftazidime-tobramycin and piperacillin/tazobactam-tobramycin combinations as 67%, and 50%, respectively, in resistant strains, whereas synergy was not detected in other combinations. The ratios of synergy were observed in ceftazidime-tobramycin, piperacillin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-ciprofloxacin and imipenem-isepamycin combinations as 31%, 46%, 15%, 8%, 8%, and respectively, in susceptible strains, whereas synergy was not detected in ciprofloxacin-tobramycin combination. Antagonism was not observed in any of the combinations.

Conclusion: Although the synergistic ratios were high in combinations with ceftazidime or piperacillin/tazobactam and tobramycin, the concentrations in these combinations could not usually reach clinically available levels. Thus, the solution of the problems caused by multiple resistant P. aeruginosa should be based on the prevention of the development of resistance and spread of the causative agent between patients.

Keywords: Pseudomonas aeruginosa; antimicrobial; combination; synergy.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

References

    1. Pier GB, Ramphal R. Pseudomonas aeruginosa. In: Mandell GL, Bennet JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 6 th edition. Volume 2. Philadelphia: Churchill Livingstone; 2005. pp. 2587–2615.
    1. Clinical and laboratory standards institute. Performance standards for antimicrobial disk susceptibility tests. CLSI Document M2-A9 9th edition. Wayne, PA, USA: CLSI; 2006.
    1. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing. CLSI Document M100-S16 16th edition. Wayne, PA, USA: CLSI; 2006.
    1. Barry AL, Thornsberry C, Jones RN, Gerlach EH. Interpretive standards for disk susceptibility tests with Sch21420 and amikacin. Antimicrob Agent Chemother. 1980;18:616–621. - PMC - PubMed
    1. Clinical and laboratory standards institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. CLSI Document M7A6 6th edition. Wayne, PA, USA: CLSI; 2003.

MeSH terms

LinkOut - more resources